LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

TB Tests May Not Detect Infection in Exposed Individual

By LabMedica International staff writers
Posted on 17 Jul 2019
Print article
Image: QuantiFERON-TB Gold (QFT) is an innovative blood test that measures the cell-mediated immune response of Mycobacterium tuberculosis infected individuals (Photo courtesy of Qiagen).
Image: QuantiFERON-TB Gold (QFT) is an innovative blood test that measures the cell-mediated immune response of Mycobacterium tuberculosis infected individuals (Photo courtesy of Qiagen).
Mycobacterium tuberculosis is the leading infectious cause of death worldwide Exposure to M. tuberculosis results in heterogeneous clinical outcomes including primary progressive tuberculosis (TB) and latent tuberculosis infection (LTBI).

M. tuberculosis infection is identified using the tuberculin skin test (TST) and interferon-γ (IFN-γ) release assay (IGRA), and a positive result may prompt chemoprophylaxis to prevent progression to tuberculosis. TST measures a delayed-type hypersensitivity reaction to purified protein derivative of the bacteria (PPD) and IFN-γ distinguishes between bacille Calmette–Guèrin (BCG) vaccination and TB infections.

An international collaboration of infectious disease experts led by the Ragon Institute (Cambridge, MA, USA) recruited 79 Ugandans, and index individuals with pulmonary TB were identified by culture for confirmed pulmonary TB. A total of 2,585 household contacts of these index cases were enrolled and followed prospectively for up to two years, aimed at identifying development of LTBI based on serial TST at 0, 3, 6, 12, 18 and 24 months, or active TB based on clinical signs and symptoms of disease and culture evaluation.

The study’s evaluation for M. tuberculosis infection status consisted of three QuantiFERON-TB Gold assays with the first at enrollment in the re-tracing study, the next two over the next two years, and a TST following the last QFT. QuantiFERON-Gold-In-Tube (QFT-GIT) was used in the present study. A Luminex isotype assay was used to quantify the relative levels of antigen-specific antibody isotypes and subclasses.

The team found 198 individuals (8.2%) who lived in these households for more than 10 years but who never tested positive on the TST or the more modern blood test interferon-gamma release assay. This meant they were either "resistant" to the M. tuberculosis infection or not being detected by the two standard tests. These ‘resisters’ possess IgM, class-switched IgG antibody responses and non-IFN-γ T cell responses to the M. tuberculosis-specific proteins ESAT6 and CFP10, immunologic evidence of exposure to M. tuberculosis. Compared to subjects with classic LTBI, ‘resisters’ display enhanced antibody avidity and distinct M. tuberculosis-specific IgG Fc profiles.

W. Henry Boom, MD, a Professor of Medicine, and a senior author of the study said, “TB remains the leading infectious cause of death worldwide, and for that reason, these findings about natural defenses by a significant sample of 8% of people exposed to TB over more than 10 years is eye-opening. This may point us to a signature among people who appear to be naturally immune that could inform vaccine development. It also is possible that we need to reconsider the standard TB tests to take into consideration for very low-level cases of TB. The study was originally published on May 20, 2019, in the journal Nature Medicine.

Related Links:
Ragon Institute

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Piezoelectric Micropump
Disc Pump

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.